Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Jung, Minkyu ^a   Koo, Ja Seung ^b   Moon, Young Wha ^a   Park, Byeong Woo ^b   Kim, Seung Il ^b   Park, Seho ^b   Lee, Soo Hyun ^a   Hong, Soojung ^a   Rha, Sun Young ^a   Chung, Hyun Cheol ^a   Kim, Joo Hang ^a   Sohn, Joohyuk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CLASS III BETA TUBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G FRAGMENT C RECEPTOR; IMMUNOGLOBULIN RECEPTOR; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC CORRELATION; GENETIC POLYMORPHISM; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGRESSION FREE SURVIVAL; SEPTIC SHOCK; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUBULIN;

EID: 84866646922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045127     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. DeVita VT, Lawrence JTS, Rosenverg SA (2008) DeVita, Hellman and Rosenberg's Cancer principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins. 1645 p.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
4. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
6. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, et al. (2009) Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7: 122-192.
7. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786-2792.
8. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, et al. (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70.
9. Clynes RA, Towers TL, Presta LG, Ravetch JV, (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446.
10. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796.
11. Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, et al. (2007) Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 43: 725-735.
12. Han H, Kim J, Park JH, Jeon YK, Lee K, et al. (2009) Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. J Korean Med Sci 24: 910-917.
13. Sève P, Dumontet C, (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9: 168-175.
14. Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, et al. (2009) Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20: 272-277.
15. Burkhart CA, Kavallaris M, Horwitz SB, (2001) The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471: O1-O9.
16. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, et al. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293.
17. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR, (1998) Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566.
18. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM, (2001) Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99: 179-186.
19. Sève P, Mackey J, Isaac S, Trédan O, Souquet PJ, et al. (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4: 2001-2007.
20. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, et al. (2006) Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12: 2774-2779.
21. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, et al. (2005) Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16Suppl 4: iv14-19.
22. Sève P, Reiman T, Lai R, Hanson J, Santos C, et al. (2007) Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60: 27-34.
23. Kuwano M, Yanagawa T, Ono M, Tsuneyoshi M, Kono S, et al. (2009) Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 15: 1473-1480.
24. Reiman T, Shepherd FA, Tsao M, Whitehead M, Seymour L, et al. (2007) Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13: 994-999.
25. Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, et al. (2008) Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 14: 4511-4516.
26. Hayes DF, Trock B, Harris AL, (1998) Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 52: 305-319.
27. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH, (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28: 92-98.
28. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, et al. (2007) FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 92: 1127-1130.
29. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, et al. (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25: 3712-3718.
30. Taylor RJ, Chan S, Wood A, Voskens CJ, Wolf JS, et al. (2009) FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 58: 997-1006.
31. Hurvitz S A, Betting D, Stern H (2009) Analysis of Fcγ receptor IIa and IIIa polymorphisms: correlation with outcome in trastuzumab-treated Her2/neu amplified early and metastatic breast cancer patients. In: SABCS, editor. 32nd Annual San Antonio Breast Cancer Symposium (SABCS), Abstract 64. San Antonio, Texas: SABCS.
32. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
33. National Cancer Institute CTEP (2010) Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). June 14.
34. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, et al. (2001) Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19: 354-363.
35. Jiang XM, Arepally G, Poncz M, McKenzie SE, (1996) Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods 199: 55-59.
36. Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, et al. (2000) A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods 242: 127-132.